

APG report

Date: Friday 07 July 2023 **Quorate:** Yes

The items in this report are supported by the area prescribing group and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

New medicines NICE TAs

Drug and indication	RAG	Notes	ICB approval
RISANKIZUMAB solution for injection on-body device (Skyrizi® ▼) for Crohn's disease	Grey	<p>Date of NICE TA publication: 17 May 2023</p> <p>Approval for implementation: 30 days after the CE mark has been granted for the on-body device (deadline TBC).</p> <p>Deadline for implementation: TBC. The on-body device is not commercially available yet, but the APG supported the proposal to progress a draft red statement to avoid delay to implementation once the CE mark is granted.</p> <p>A grey statement has been produced to clarify the current position.</p>	<p>Grey statement approved by ICB Medicines Optimisation and Pharmacy (MOP) Group 18/7/23.</p> <p>Draft red statement supported by ICB MOP Group 18/7/23. To go to ICB Finance, Investment and Resources Committee (FIRC) for ICB approval when the CE mark has been granted for the on-body device.</p>
UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for Crohn's disease	Red	<p>Date of NICE TA publication: 21 June 2023</p> <p>Approval for implementation: 30 days</p>	<p>Approved by ICB MOP Group 18/7/23</p>

Drug and indication	RAG	Notes	ICB approval
		<p>Deadline for implementation: 19 July 2023</p> <p>Red statement in line with TA905. Upadacitinib is recommended as an option for treating moderately to severely active Crohn's disease in adults, only if certain criteria are met. This is a new, oral treatment option with a different mode of action from existing biologic treatment options.</p> <p>Modelling within the NICE resource impact template estimates that implementing TA905 will likely be cost-neutral, with the potential for a cost-saving, based on the NHS list price.</p>	

New medicines other

Drug and indication	RAG	Notes	ICB approval
TIRBANIBULIN 10mg/g ointment (Klisyri® ▼) for actinic keratosis	Amber initiated	<p>An in-year application was submitted by LUHFT, prior to the formation of the new Cheshire and Merseyside APG, and an amber initiated statement has been produced. Tirbanibulin was already approved for use in Cheshire with an amber initiated RAG rating.</p> <p>The APG supported the amber initiated RAG rating as a pragmatic solution which will provide equitable patient access across Cheshire and Merseyside. However, it was acknowledged that the RAG may change in the future when the formulary chapter is reviewed.</p> <p>Based on an estimate of 1200 patients per year across Cheshire and Merseyside, there will be an additional cost of £12,480 per year if used in place of Aldara® as a second line option, or £31,320 per year if used in place of Efudix® as a first line option.</p>	Approved by ICS Chief Pharmacist at ICB MOP Group 18/7/23
SECUKINUMAB solution for injection (Cosentyx®) for enthesitis-related arthritis or juvenile psoriatic arthritis	Grey	<p>Holding statement. Not recommended until NICE TA published.</p> <p>For noting.</p>	Approved by ICB MOP Group 18/7/23

APG governance documents

Drug and indication	RAG	Notes	ICB approval
CMAPG organogram	N/A	The updated organogram will be added to the APG Policy as an appendix as part of the first APG Policy review. For noting.	Approved by ICB MOP Group 18/7/23 - to go to ICB Clinical Effectiveness Group (CEG) 9/8/23 for noting.

APG reports

Drug and indication	Date	Notes	ICB approval
NICE TA formulary adherence	May 2023	For noting	Noted by ICB MOP Group 18/7/23